{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:49:41Z","timestamp":1791503381591,"version":"4.3.4"},"reference-count":84,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals USA Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim Corp USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.dmd.2026.100401","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:26:46Z","timestamp":1788910006000},"page":"100401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interindividual variability in hepatic hydrolytic enzymes: Effects of age, sex, and race on the abundance of drug-metabolizing hydrolases"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7248-6714","authenticated-orcid":false,"given":"Dilip Kumar","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8537-6047","authenticated-orcid":false,"given":"Deepak","family":"Ahire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7805-3522","authenticated-orcid":false,"given":"Scott","family":"Heyward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5283-8070","authenticated-orcid":false,"given":"Robert S.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Cyrus","family":"Khojasteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4889-8385","authenticated-orcid":false,"given":"Ryota","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7549-2658","authenticated-orcid":false,"given":"Bin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard P.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8713-9889","authenticated-orcid":false,"given":"Bill J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8577-1714","authenticated-orcid":false,"given":"David M.","family":"Stresser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0300-726X","authenticated-orcid":false,"given":"Mitchell E.","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9090-0912","authenticated-orcid":false,"given":"Bhagwat","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.dmd.2026.100401_bib1","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cpt.3250","article-title":"Assessment of dosing strategies for pediatric drug products","volume":"116","author":"Taylor","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmd.2026.100401_bib2","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1124\/pharmrev.120.000071","article-title":"Ontogeny of hepatic transporters and drug-metabolizing enzymes in humans and in nonclinical species","volume":"73","author":"van Groen","year":"2021","journal-title":"Pharmacol Rev"},{"issue":"4","key":"10.1016\/j.dmd.2026.100401_bib3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.livres.2025.10.003","article-title":"Sex differences in hepatic enzymes and transporters involved in pharmacokinetics","volume":"9","author":"Behal","year":"2025","journal-title":"Liver Res"},{"issue":"1","key":"10.1016\/j.dmd.2026.100401_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1559-0275-8-12","article-title":"Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance","volume":"8","author":"Wu","year":"2011","journal-title":"Clin Proteomics"},{"issue":"6","key":"10.1016\/j.dmd.2026.100401_bib5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1517\/17425251003677755","article-title":"Altered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymes","volume":"6","author":"Jeong","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100401_bib6","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/clpt.2008.141","article-title":"The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies","volume":"84","author":"Yasuda","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100401_bib7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/17425255.2021.1858051","article-title":"Potential implications of DMET ontogeny on the disposition of commonly prescribed drugs in neonatal and pediatric intensive care units","volume":"17","author":"Naji-Talakar","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100401_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/psp4.70174","article-title":"Population physiologically-based pharmacokinetic modeling to determine ontogeny: a quantitative clinical pharmacology example in pediatric rare disease","volume":"15","author":"Cleary","year":"2026","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"7","key":"10.1016\/j.dmd.2026.100401_bib9","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1124\/dmd.115.068031","article-title":"Physiologically based pharmacokinetic modeling in pediatric oncology drug development","volume":"44","author":"Rioux","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2026.100401_bib10","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cpt.3354","article-title":"Age-dependent abundance of CYP450 enzymes involved in metronidazole metabolism: application to pediatric PBPK modeling","volume":"116","author":"Parvez","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.dmd.2026.100401_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70247","article-title":"Best pharmaceuticals for children act pediatric trials network steering committee. Physiologically based and population pharmacokinetic modeling of midazolam in children with obesity using real-world data","volume":"18","author":"McCann","year":"2025","journal-title":"Clin Transl Sci"},{"issue":"7","key":"10.1016\/j.dmd.2026.100401_bib12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/psp4.12306","article-title":"PBPK model of morphine incorporating developmental changes in hepatic OCT1 and UGT2B7 proteins to explain the variability in clearances in neonates and small infants","volume":"7","author":"Emoto","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"9","key":"10.1016\/j.dmd.2026.100401_bib13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/bdd.2208","article-title":"WB-PBPK approach in predicting zidovudine pharmacokinetics in preterm neonates","volume":"40","author":"Wei","year":"2019","journal-title":"Biopharm Drug Dispos"},{"issue":"10","key":"10.1016\/j.dmd.2026.100401_bib14","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/jcph.1133","article-title":"Development of a physiologically based pharmacokinetic model of ethionamide in the pediatric population by integrating flavin-containing monooxygenase 3 maturational changes over time","volume":"58","author":"Nguyen","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100401_bib15","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/psp4.13255","article-title":"Establishing a physiologically based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase-CYP substrates","volume":"14","author":"Izat","year":"2025","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"10.1016\/j.dmd.2026.100401_bib16","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1124\/dmd.119.086462","article-title":"Ontogeny of hepatic sulfotransferases and prediction of age-dependent fractional contribution of sulfation in acetaminophen metabolism","volume":"47","author":"Ladumor","year":"2019","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100401_bib17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1124\/dmd.116.072652","article-title":"Age-dependent absolute abundance of hepatic carboxylesterases (CES1 and CES2) by LC-MS\/MS proteomics: application to PBPK modeling of oseltamivir in vivo pharmacokinetics in infants","volume":"45","author":"Boberg","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100401_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117044","article-title":"Inter-individual variability, differential tissue abundance, and sub-cellular localization of human aldo-keto reductases (AKRs) and hydroxy-steroid dehydrogenases (HSDs)","volume":"239","author":"Bachhav","year":"2025","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"10.1016\/j.dmd.2026.100401_bib19","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1124\/dmd.118.081810","article-title":"Age-related changes in expression and activity of human hepatic mitochondrial glutathione transferase zeta1","volume":"46","author":"Zhong","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100401_bib20","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1124\/dmd.115.068957","article-title":"Age-dependent human hepatic carboxylesterase 1 (CES1) and carboxylesterase 2 (CES2) postnatal ontogeny","volume":"44","author":"Hines","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100401_bib21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev-pharmtox-052220-105907","article-title":"Non-P450 drug-metabolizing enzymes: contribution to drug disposition, toxicity, and development","volume":"62","author":"Fukami","year":"2022","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100401_bib22","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1021\/acsptsci.1c00016","article-title":"Tissue-specific proteomics analysis of anti-COVID-19 nucleoside and nucleotide prodrug-activating enzymes provides insights into the optimization of prodrug design and pharmacotherapy strategy","volume":"4","author":"Li","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"5","key":"10.1016\/j.dmd.2026.100401_bib23","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3390\/bioengineering12050481","article-title":"Peptide-drug conjugates as next-generation therapeutics: exploring the potential and clinical progress","volume":"12","author":"Jadhav","year":"2025","journal-title":"Bioengineering (Basel)"},{"key":"10.1016\/j.dmd.2026.100401_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1274088","article-title":"A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy","volume":"14","author":"Riccardi","year":"2023","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.dmd.2026.100401_bib25","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1124\/dmd.123.001370","article-title":"In vivo metabolite profiles of an N-acetylgalactosamine-conjugated antisense oligonucleotide AZD8233 using liquid chromatography high-resolution mass spectrometry: a cross-species comparison in animals and humans","volume":"51","author":"Li","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100401_bib26","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3762\/bjoc.14.64","article-title":"Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin-GnRH-III conjugates developed for targeted drug delivery","volume":"14","author":"Schuster","year":"2018","journal-title":"Beilstein J Org Chem"},{"issue":"6","key":"10.1016\/j.dmd.2026.100401_bib27","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/cpt.3409","article-title":"Developmental expression of drug transporters and conjugating enzymes involved in enterohepatic recycling: implication for pediatric drug dosing","volume":"116","author":"Thakur","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.dmd.2026.100401_bib28","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1124\/dmd.124.001608","article-title":"Age-dependent changes in cytochrome P450 abundance and composition in human liver","volume":"52","author":"Subash","year":"2024","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100401_bib29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41592-019-0638-x","article-title":"DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput","volume":"17","author":"Demichev","year":"2020","journal-title":"Nat Methods"},{"key":"10.1016\/j.dmd.2026.100401_bib30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/bs.mie.2016.10.002","article-title":"Label-free and standard-free absolute quantitative proteomics using the \u201ctotal protein\u201d and \u201cproteomic ruler\u201d approaches","volume":"585","author":"Wi\u015bniewski","year":"2017","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.dmd.2026.100401_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jprot.2019.03.005","article-title":"Label-free absolute protein quantification with data-independent acquisition","volume":"200","author":"He","year":"2019","journal-title":"J Proteomics"},{"key":"10.1016\/j.dmd.2026.100401_bib32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.tox.2015.02.007","article-title":"Ontogenic expression of human carboxylesterase-2 and cytochrome P450 3A4 in liver and duodenum: postnatal surge and organ-dependent regulation","volume":"330","author":"Chen","year":"2015","journal-title":"Toxicology"},{"issue":"16","key":"10.1016\/j.dmd.2026.100401_bib33","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.3390\/ijms20163891","article-title":"Vanin 1: its physiological function and role in diseases","volume":"20","author":"Bartucci","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.dmd.2026.100401_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.70274","article-title":"Revealing VNN1: an emerging and promising target for inflammation and redox balance","volume":"13","author":"Lv","year":"2025","journal-title":"Immun Inflamm Dis"},{"issue":"2","key":"10.1016\/j.dmd.2026.100401_bib35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1399-0004.2011.01728.x","article-title":"5-Oxoprolinase deficiency: report of the first human OPLAH mutation","volume":"82","author":"Almaghlouth","year":"2012","journal-title":"Clin Genet"},{"issue":"1\u20132","key":"10.1016\/j.dmd.2026.100401_bib36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ymgme.2016.07.008","article-title":"Unravelling 5-oxoprolinuria (pyroglutamic aciduria) due to bi-allelic OPLAH mutations: 20 new mutations in 14 families","volume":"119","author":"Sass","year":"2016","journal-title":"Mol Genet Metab"},{"issue":"12","key":"10.1016\/j.dmd.2026.100401_bib37","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1021\/acs.molpharmaceut.5c00462","article-title":"Confounding effect of hepatic carboxylesterase 1 (CES1) variability on clopidogrel oxidation","volume":"22","author":"Subash","year":"2025","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.dmd.2026.100401_bib38","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12967-018-1463-1","article-title":"Association of genetic polymorphisms in genes involved in Ara-C and DNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML)","volume":"16","author":"Zhu","year":"2018","journal-title":"J Transl Med"},{"issue":"11","key":"10.1016\/j.dmd.2026.100401_bib39","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1182\/bloodadvances.2022009088","article-title":"SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia","volume":"7","author":"Marrero","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.dmd.2026.100401_bib40","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1124\/dmd.113.051482","article-title":"Interindividual variability of carboxymethylenebutenolidase homolog, a novel olmesartan medoxomil hydrolase, in the human liver and intestine","volume":"41","author":"Ishizuka","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100401_bib41","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1124\/dmd.111.041475","article-title":"Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism","volume":"40","author":"Ishizuka","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"13","key":"10.1016\/j.dmd.2026.100401_bib42","doi-asserted-by":"crossref","first-page":"15391","DOI":"10.1021\/acs.jmedchem.6c00165","article-title":"Protein abundance of hydrolytic drug metabolizing enzymes in different tissues and across species","volume":"69","author":"Subash","year":"2026","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.dmd.2026.100401_bib43","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1124\/dmd.114.059485","article-title":"An orphan esterase ABHD10 modulates probenecid acyl glucuronidation in human liver","volume":"42","author":"Ito","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.dmd.2026.100401_bib44","doi-asserted-by":"crossref","first-page":"9240","DOI":"10.1074\/jbc.M111.271288","article-title":"Human \u03b1\/\u03b2 hydrolase domain containing 10 (ABHD10) is responsible enzyme for deglucuronidation of mycophenolic acid acyl-glucuronide in liver","volume":"287","author":"Iwamura","year":"2012","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.dmd.2026.100401_bib45","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1124\/dmd.110.032938","article-title":"Identification of valproic acid glucuronide hydrolase as a key enzyme for the interaction of valproic acid with carbapenem antibiotics","volume":"38","author":"Suzuki","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2026.100401_bib46","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1734-1140(12)70919-2","article-title":"Contribution of the \u03b2-ureidopropionase (UPB1) gene alterations to the development of fluoropyrimidine-related toxicity","volume":"64","author":"Fidlerova","year":"2012","journal-title":"Pharmacol Rep"},{"issue":"5","key":"10.1016\/j.dmd.2026.100401_bib47","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10545-014-9682-y","article-title":"Clinical, biochemical and molecular analysis of 13 Japanese patients with \u03b2-ureidopropionase deficiency demonstrates high prevalence of the c.977G > A (p. R326Q) mutation [corrected]","volume":"37","author":"Nakajima","year":"2014","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"10.1016\/j.dmd.2026.100401_bib48","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1373\/clinchem.2007.099044","article-title":"Factors associated with paraoxonase genotypes and activity in a diverse, young, healthy population: the Coronary Artery Risk Development in Young Adults (CARDIA) Study","volume":"54","author":"Thyagarajan","year":"2008","journal-title":"Clin Chem"},{"issue":"8","key":"10.1016\/j.dmd.2026.100401_bib49","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1289\/ehp.0900569","article-title":"Racial differences in paraoxonase-1 (PON1): a factor in the health of southerners?","volume":"117","author":"Davis","year":"2009","journal-title":"Environ Health Perspect"},{"issue":"9","key":"10.1016\/j.dmd.2026.100401_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100145","article-title":"Characterization of hydrolase activity in ocular tissues of humans and preclinical species","volume":"53","author":"Li","year":"2025","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100401_bib51","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bcp.2018.01.028","article-title":"Presence and inter-individual variability of carboxylesterases (CES1 and CES2) in human lung","volume":"150","author":"Gabriele","year":"2018","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100401_bib52","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1124\/dmd.114.057620","article-title":"Identification of bioactivating enzymes involved in the hydrolysis of laninamivir octanoate, a long-acting neuraminidase inhibitor, in human pulmonary tissue","volume":"42","author":"Koyama","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"633","key":"10.1016\/j.dmd.2026.100401_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl8282","article-title":"Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection","volume":"14","author":"Vermillion","year":"2022","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.dmd.2026.100401_bib54","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1124\/dmd.121.000476","article-title":"Quantitative investigation of irinotecan metabolism, transport, and gut microbiome activation","volume":"49","author":"Parvez","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.dmd.2026.100401_bib55","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1124\/dmd.123.001266","article-title":"Evaluation of drug-drug interactions via inhibition of hydrolases by orlistat, an anti-obesity drug","volume":"51","author":"Hirosawa","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100401_bib56","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/j.dmd.2026.100401_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100227","article-title":"Preclinical translational physiologically based pharmacokinetic modeling for predicting human pharmacokinetics of proteolysis targeting chimeras: case studies of vepdegestrant (ARV-471) and bavdegalutamide (ARV-110)","volume":"54","author":"Rachumallu","year":"2026","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmd.2026.100401_bib58","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1124\/dmd.123.001437","article-title":"Metabolism and excretion of therapeutic peptides: current industry practices, perspectives, and recommendations","volume":"51","author":"He","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"24","key":"10.1016\/j.dmd.2026.100401_bib59","doi-asserted-by":"crossref","first-page":"25689","DOI":"10.1021\/acs.jmedchem.5c02276","article-title":"Overcoming challenges in the metabolism of peptide therapeutics: strategies and case studies for clinical success","volume":"68","author":"Ma","year":"2025","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.dmd.2026.100401_bib60","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1124\/dmd.122.001154","article-title":"Industry perspective on the pharmacokinetic and absorption, distribution, metabolism, and excretion characterization of heterobifunctional protein degraders","volume":"51","author":"Volak","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100401_bib61","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/s41467-018-04982-3","article-title":"Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice","volume":"9","author":"Anami","year":"2018","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.dmd.2026.100401_bib62","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.3390\/biomedicines11113080","article-title":"Lysosomal-cleavable peptide linkers in antibody-drug conjugates","volume":"11","author":"Balamkundu","year":"2023","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.dmd.2026.100401_bib63","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12951-025-03277-2","article-title":"Current progress and remaining challenges of peptide-drug conjugates (PDCs): next generation of antibody-drug conjugates (ADCs)?","volume":"23","author":"Wang","year":"2025","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100401_bib64","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s10555-024-10231-5","article-title":"Influence of antibody-drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: a systematic review and meta-analysis","volume":"44","author":"Tang","year":"2024","journal-title":"Cancer Metastasis Rev"},{"issue":"8","key":"10.1016\/j.dmd.2026.100401_bib65","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1210\/jc.2012-2396","article-title":"Mechanism of action of DPP-4 inhibitors\u2014new insights","volume":"97","author":"Vella","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"9\u201310","key":"10.1016\/j.dmd.2026.100401_bib66","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.drudis.2010.02.003","article-title":"Angiotensin-converting enzymes and drug discovery in cardiovascular diseases","volume":"15","author":"Shi","year":"2010","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.dmd.2026.100401_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115741","article-title":"Nucleoside-based anticancer drugs: mechanism of action and drug resistance","volume":"215","author":"Hruba","year":"2023","journal-title":"Biochem Pharmacol"},{"issue":"50","key":"10.1016\/j.dmd.2026.100401_bib68","doi-asserted-by":"crossref","first-page":"31838","DOI":"10.1073\/pnas.2013473117","article-title":"A hybrid approach reveals the allosteric regulation of GTP cyclohydrolase I","volume":"117","author":"Ebenhoch","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.dmd.2026.100401_bib69","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s12672-025-02112-2","article-title":"The role of fructose-1,6-bisphosphatase 1 on regulating the cancer progression and drug resistance","volume":"16","author":"Wang","year":"2025","journal-title":"Discov Oncol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100401_bib70","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ijc.27706","article-title":"Inhibition of GTP cyclohydrolase attenuates tumor growth by reducing angiogenesis and M2-like polarization of tumor associated macrophages","volume":"132","author":"Pickert","year":"2013","journal-title":"Int J Cancer"},{"issue":"48","key":"10.1016\/j.dmd.2026.100401_bib71","doi-asserted-by":"crossref","first-page":"5186","DOI":"10.1038\/s41388-022-02507-3","article-title":"OTUB1 suppresses hippo signaling via modulating YAP protein in gastric cancer","volume":"41","author":"Yan","year":"2022","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.dmd.2026.100401_bib72","first-page":"684","article-title":"Potential inhibitors of the OTUB1 catalytic site to develop an anti-cancer drug using in-silico approaches","volume":"11","author":"Galindo-Hern\u00e1ndez","year":"2023","journal-title":"Rep Biochem Mol Biol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100401_bib73","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.athoracsur.2024.05.019","article-title":"Phase 2 clinical trial of VGT-309 for intraoperative molecular imaging during pulmonary resection","volume":"119","author":"Bou-Samra","year":"2025","journal-title":"Ann Thorac Surg"},{"issue":"11","key":"10.1016\/j.dmd.2026.100401_bib74","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1124\/dmd.120.000131","article-title":"Evaluation of the disconnect between hepatocyte and microsome intrinsic clearance and in vitro in vivo extrapolation performance","volume":"48","author":"Williamson","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.dmd.2026.100401_bib75","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1124\/dmd.123.001417","article-title":"Ontogeny of scaling factors for pediatric physiologically based pharmacokinetic modeling and simulation: cytosolic protein per gram of liver","volume":"51","author":"Stancil","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2026.100401_bib76","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/AAC.00128-15","article-title":"Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy","volume":"59","author":"Murakami","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.dmd.2026.100401_bib77","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1124\/dmd.120.000323","article-title":"Contributions of cathepsin A and carboxylesterase 1 to the hydrolysis of tenofovir alafenamide in the human liver, and the effect of CES1 genetic variation on tenofovir alafenamide hydrolysis","volume":"50","author":"Li","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2026.100401_bib78","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/0091270007299930","article-title":"Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs","volume":"47","author":"Urquhart","year":"2007","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100401_bib79","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.dmpk.2016.10.409","article-title":"Sex- and age-dependent gene expression in human liver: an implication for drug-metabolizing enzymes","volume":"32","author":"Uno","year":"2017","journal-title":"Drug Metab Pharmacokinet"},{"issue":"3","key":"10.1016\/j.dmd.2026.100401_bib80","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1432-1033.1996.00683.x","article-title":"Differential developmental and tissue-specific regulation of expression of the genes encoding three members of the flavin-containing monooxygenase family of man, FMO1, FMO3 and FM04","volume":"235","author":"Dolphin","year":"1996","journal-title":"Eur J Biochem"},{"issue":"6","key":"10.1016\/j.dmd.2026.100401_bib81","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.bcp.2010.04.034","article-title":"Functions and transcriptional regulation of adult human hepatic UDP-glucuronosyl-transferases (UGTs): mechanisms responsible for interindividual variation of UGT levels","volume":"80","author":"Bock","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.dmd.2026.100401_bib82","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.tox.2019.01.014","article-title":"Hepatic carboxylesterases are differentially regulated in PPAR\u03b1-null mice treated with perfluorooctanoic acid","volume":"416","author":"Wen","year":"2019","journal-title":"Toxicology"},{"issue":"1","key":"10.1016\/j.dmd.2026.100401_bib83","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1124\/dmd.112.048397","article-title":"Carboxylesterases are uniquely expressed among tissues and regulated by nuclear hormone receptors in the mouse","volume":"41","author":"Jones","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmd.2026.100401_bib84","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1124\/dmd.123.001609","article-title":"Regulation of human hydrolases and its implications in pharmacokinetics and pharmacodynamics","volume":"52","author":"Jung","year":"2024","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006707?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006707?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:07:32Z","timestamp":1791500852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":84,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0090955626006707"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100401","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interindividual variability in hepatic hydrolytic enzymes: Effects of age, sex, and race on the abundance of drug-metabolizing hydrolases","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100401","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100401"}}